Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
6 papers
Recent·Most cited
M. CHALABI-DCHAR, O. VILLERONCE, J. RIPOLL, A. VINCENT, T. FENOUIL, R. KHOUEIRY, J. KUCHARCZAK, L. JENTSCHEL, F. CATEZ, A. M. Vigneron, J. TREGUIER, C. MANDIER, C. BOUCLIER, J. VITRE, L. LAGERQVIST, , J.-J. DIAZ
The paper shows 5-FU induces translational reprogramming in colorectal cancer cells, enhancing drug tolerance through pro-tumoral gene expression and IL-8 overexpression.
bioRxiv · Jul 3, 2024 · PreprintCancer Biology
P. Deschamps, M. Wacheux, A. Gosseye, M. Morabito, A. Pages, A.-M. Lyne, A. Alfaro, P. Rameau, A. Imanci, R. Chelbi, V. Marchand, A. Renneville, M. M. Patnaik, V. Lapierre, B. Badaoui, , D. Selimoglu-Buet
The paper identifies CXCL8 secreted by immature granulocytes as a factor inhibiting wildtype hematopoiesis in CMML, suggesting CXCL8 blockade could slow disease progression.
bioRxiv · Mar 8, 2024Cancer Biology
D. Hidaoui, A. Porquet, R. Chelbi, M. Bohm, A. Polizou, V. Alcazer, S. Depil, A. Imanci, M. Morabito, A. Renneville, D. Selimoglu-Buet, S. Thepot, R. Itzykson, L. Laplane, N. Droin, , F. PORTEU
This study shows that combining DNA hypomethylating agents with H3K9me2 inhibitors reactivates immune pathways and eliminates malignant stem cells in CMML by targeting heterochromatin disorganization.
bioRxiv · Feb 2, 2024Cancer Biology
A. ALLOUCH, L. VOISIN, Y. ZHANG, R. SYED, Y. LECLUSE, J. CALVO, D. Selimoglu-Buet, S. DE BOTTON, F. LOUACHE, F. PFLUMIO, E. SOLARY, j.-l. PERFETTINI
This study shows that overexpressing CDKN1A in macrophages enhances their ability to phagocytose leukemic cells, leading to pro-inflammatory reprogramming and improved survival in mouse models.
bioRxiv · Jan 18, 2022Immunology
S. Ragu, G. Matos-Rodrigues, N. Droin, A. Barascu, S. Caillat, G. Zarkovic, C. Siberchicot, E. Dardillac, C. Gelot, J. P. Radicella, A. A. Ishchenko, J.-L. Ravanat, E. Solary, B. S. Lopez
The paper identifies a pre-DDR response in human fibroblasts that protects genome integrity without arresting cell cycle progression by managing ROS levels below a stress threshold.
bioRxiv · May 13, 2020 · PreprintCell Biology
R. M. Carr, D. Vorobyev, T. Lasho, D. L. Marks, E. J. Tolosa, A. Vedder, L. Almada, A. Yurchenko, I. Padioleau, B. Alver, G. Coltro, M. Binder, S. L. Safgren, I. Horn, X. You, , M. M. Patnaik
This study identifies RAS mutations as drivers of proliferative CMML through a novel KMT2A-PLK1 axis, showing PLK1 inhibition can improve disease outcomes in patient-derived xenografts.
bioRxiv · Dec 23, 2019 · PreprintCancer Biology